Denali Therapeutics ( (DNLI) ) has shared an update.
On February 27, 2025, Denali Therapeutics entered into a new equity distribution agreement with Goldman Sachs and Leerink Partners, allowing the company to sell up to $400 million in common stock through an at-the-market offering program. This agreement replaces a prior sales agreement terminated on the same date. Denali also reported significant progress in its clinical programs, particularly with its Enzyme Transport Vehicle (ETV) programs, and plans for the potential U.S. commercial launch of tividenofusp alfa for Hunter syndrome in late 2025 or early 2026. The company is actively preparing for this launch and continues to advance its pipeline, including programs for Sanfilippo syndrome and frontotemporal dementia.
More about Denali Therapeutics
Denali Therapeutics is a biopharmaceutical company focused on developing therapies for neurodegenerative and lysosomal storage diseases. The company specializes in engineering product candidates to cross the blood-brain barrier, targeting genetically validated pathways and utilizing biomarkers for development guidance. Based in South San Francisco, Denali is advancing a broad portfolio of therapeutic candidates.
YTD Price Performance: -9.36%
Average Trading Volume: 908,594
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $2.72B
Find detailed analytics on DNLI stock on TipRanks’ Stock Analysis page.